Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

105.78 +0.52 (+0.49%)

Streaming Delayed Price Updated: 12:24 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Via StockStory

Topics Economy World Trade

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

November 21, 2025

From Merck & Co., Inc.

Via Business Wire

Goldman Sachs Just Delivered Bad News for U.S. Investors ... Sort Of. Here's What You Need to Know. ↗

November 21, 2025

The investment bank's analysts simply recognize how much has changed in just the past few years, and what that means for the near future.

Via The Motley Fool

Topics Artificial Intelligence Economy

Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices ↗

November 20, 2025

Via Stocktwits

Topics Workforce

Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs? ↗

November 20, 2025

The pharmaceutical giant's post-Keytruda plans continue to take shape.

Via The Motley Fool

Topics Intellectual Property

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗

November 20, 2025

Shares in the biotech company have surged on news of a big pharma takeover.

Via The Motley Fool

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? ↗

November 19, 2025

Via MarketBeat

Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment ↗

November 19, 2025

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Via Benzinga

Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study ↗

November 19, 2025

Via Stocktwits

2 Healthcare Stocks Worth Your Attention and 1 We Ignore

November 19, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and...

Via StockStory

Topics Stocks

Why GRAIL Stock Could Be Biotech’s Next Big Breakout ↗

November 19, 2025

Via MarketBeat

Healthcare Rotation Underway: 3 Stocks Leading the Charge ↗

November 19, 2025

Via MarketBeat

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection

November 19, 2025

From Merck & Co., Inc.

Via Business Wire

European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union

November 19, 2025

From Merck & Co., Inc.

Via Business Wire

Healthcare Sector Navigates Volatile Markets: A Defensive Anchor or Driven by Innovation?

November 18, 2025

As broader markets grapple with persistent volatility on November 18, 2025, the healthcare sector within the S&P 500 (SPX) finds itself under intense scrutiny. Traditionally viewed as a stalwart...

Via MarketMinute

Topics ETFs Economy Intellectual Property

Which S&P500 stocks are moving on Tuesday? ↗

November 18, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.

Via Chartmill

Market Movers in Motion: Merck & Co. and Amer Sports Chart Volatile Courses

November 18, 2025

The financial markets are a constant theater of dynamic shifts, and in recent months, two distinct players – pharmaceutical giant Merck & Co. and global sporting goods powerhouse Amer Sports – have...

Via MarketMinute

Topics Economy Initial Public Offering Intellectual Property

Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything ↗

November 18, 2025

Via MarketBeat

Tech Stocks Drop, Pharma Gains As Sector Rotation Picks Up: What's Moving Markets Tuesday? ↗

November 18, 2025

Wall Street endured another wave of selling in tech stocks on Tuesday, with the Nasdaq 100 down more than 1% by midday in New York, extending its month-to-date slide to more than 5%.

Via Benzinga

Which S&P500 stocks have an unusual volume on Tuesday? ↗

November 18, 2025

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the S&P500 stocks with an unusual volume in today's session.

Via Chartmill

Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition ↗

November 18, 2025

Merck's Winrevair drug achieved its primary goal in the Phase 2 CADENCE study for combined post- and pre-capillary pulmonary hypertension due to HFpEF.

Via Benzinga

Uncover the latest developments among S&P500 stocks in today's session. ↗

November 18, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

Merck Announces First-Quarter 2026 Dividend

November 18, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Jumps On A Surprise Win; Why It Still Has A Long Road To Go ↗

November 18, 2025

Merck stock jumped Tuesday on a surprise win for its drug, sotatercept, in patients with pulmonary hypertension.

Via Investor's Business Daily

Topics Government

Top S&P500 movers in Tuesday's pre-market session ↗

November 18, 2025

Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics.

Via Chartmill

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗

November 18, 2025

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.

Via Investor's Business Daily

Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)

November 18, 2025

From Merck & Co., Inc.

Via Business Wire

Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring ↗

November 17, 2025

AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer.

Via Benzinga

Topics Artificial Intelligence

Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight ↗

November 17, 2025

With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation.

Via Benzinga

Topics ETFs

Market Grapples with Valuation Fears Amidst Accelerating Sector Rotation

November 17, 2025

As November 2025 unfolds, the global financial markets find themselves at a critical juncture, characterized by a palpable sense of unease over elevated valuations in specific sectors and a pronounced...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.